These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 2267294)

  • 1. Current therapy of the Lambert-Eaton myasthenic syndrome.
    Lundh H; Nilsson O; Rosén I
    Prog Brain Res; 1990; 84():163-70. PubMed ID: 2267294
    [No Abstract]   [Full Text] [Related]  

  • 2. Available treatment options for the management of Lambert-Eaton myasthenic syndrome.
    Verschuuren JJ; Wirtz PW; Titulaer MJ; Willems LN; van Gerven J
    Expert Opin Pharmacother; 2006 Jul; 7(10):1323-36. PubMed ID: 16805718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The drug treatment of the Lambert-Eaton myasthenic syndrome].
    Danilov AF
    Eksp Klin Farmakol; 1999; 62(6):69-71. PubMed ID: 10650534
    [No Abstract]   [Full Text] [Related]  

  • 4. [Lambert-Eaton myasthenic syndrome].
    Sahashi K
    Nihon Rinsho; 1990 Jul; 48(7):1477-82. PubMed ID: 2402065
    [No Abstract]   [Full Text] [Related]  

  • 5. Wide spectrum of symptomatic treatment in Lambert-Eaton myasthenic syndrome.
    Oh SJ; Kim DS; Kwon KH; Tseng A; Mussell H; Claussen GC
    Ann N Y Acad Sci; 1998 May; 841():827-31. PubMed ID: 9668337
    [No Abstract]   [Full Text] [Related]  

  • 6. Therapy in myasthenia gravis and Lambert-Eaton myasthenic syndrome.
    Newsom-Davis J
    Semin Neurol; 2003 Jun; 23(2):191-8. PubMed ID: 12894384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful alternate day guanidine therapy following guanidine-induced neutropenia in the Lambert-Eaton myasthenic syndrome.
    Silbert PL; Hankey GJ; Barr AL
    Muscle Nerve; 1990 Apr; 13(4):360-1. PubMed ID: 2355949
    [No Abstract]   [Full Text] [Related]  

  • 8. Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic.
    ; Jacob S; Muppidi S; Guidon A; Guptill J; Hehir M; Howard JF; Illa I; Mantegazza R; Murai H; Utsugisawa K; Vissing J; Wiendl H; Nowak RJ
    J Neurol Sci; 2020 May; 412():116803. PubMed ID: 32247193
    [No Abstract]   [Full Text] [Related]  

  • 9. [Favourable outcome after treatment with rituximab in a case of seronegative non-paraneoplastic Lambert-Eaton myasthenic syndrome].
    Boutin E; Rey C; Romeu M; Pouget J; Franques J
    Rev Med Interne; 2013 Aug; 34(8):493-6. PubMed ID: 23759215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cyclosporin A in the treatment of Eaton-Lambert myasthenic syndrome].
    Yuste Ara JR; Beloqui Ruiz O; Artieda Gonzalez-Granda J; Herrero Santos JI; De la Peña Fernandez A; Prieto Valtueña J
    An Med Interna; 1996 Jan; 13(1):25-6. PubMed ID: 8679819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose guanidine and pyridostigmine: relatively safe and effective long-term symptomatic therapy in Lambert-Eaton myasthenic syndrome.
    Oh SJ; Kim DS; Head TC; Claussen GC
    Muscle Nerve; 1997 Sep; 20(9):1146-52. PubMed ID: 9270671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lambert-Eaton myasthenic syndrome: evaluation of movement performance following drug therapy.
    Cooke JD; Hefter H; Brown SH; Toyka KV; Freund HJ
    Electromyogr Clin Neurophysiol; 1994 Mar; 34(2):87-93. PubMed ID: 8187683
    [No Abstract]   [Full Text] [Related]  

  • 13. Lambert-Eaton myasthenic syndrome in childhood.
    Kostera-Pruszczyk A; Ryniewicz B; Rowinska-Marcinska K; Dutkiewicz M; Kamińska A
    Eur J Paediatr Neurol; 2009 Mar; 13(2):194-6. PubMed ID: 18585938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic approaches to Lambert-Eaton myasthenic syndrome in the intra-individual comparison.
    Jost WH; Mielke U; Schimrigk K
    Wien Klin Wochenschr; 1991; 103(20):629-32. PubMed ID: 1763511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term follow-up in infantile-onset lambert-eaton myasthenic syndrome.
    Portaro S; Parisi D; Polizzi A; Ruggieri M; Andreetta F; Bernasconi P; Toscano A; Rodolico C
    J Child Neurol; 2014 Sep; 29(9):NP58-61. PubMed ID: 24114606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment for Lambert-Eaton myasthenic syndrome.
    Maddison P; Newsom-Davis J
    Cochrane Database Syst Rev; 2003; (2):CD003279. PubMed ID: 12804456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of the paraneoplastic Lambert-Eaton syndrome].
    Courau E; Westeel V; Jacoulet P; Depierre A
    Rev Pneumol Clin; 1998 May; 54(2):65-70. PubMed ID: 9769989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-paraneoplastic Lambert-Eaton myasthenic syndrome: a brief review of 10 cases.
    Lorenzoni PJ; Scola RH; Kay CS; Parolin SF; Werneck LC
    Arq Neuropsiquiatr; 2010 Dec; 68(6):849-54. PubMed ID: 21243240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lambert-Eaton myasthenic syndrome (LEMS). Clinical and electrodiagnostic features and response to therapy in 59 patients.
    Tim RW; Massey JM; Sanders DB
    Ann N Y Acad Sci; 1998 May; 841():823-6. PubMed ID: 9668336
    [No Abstract]   [Full Text] [Related]  

  • 20. Pediatric Lambert-Eaton Myasthenic Syndrome.
    Avina Fierro JA; Hernandez Avina DA
    Minerva Pediatr; 2017 Apr; 69(2):161-162. PubMed ID: 28178777
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.